ERBB2 and breast neoplasm: As reported in recent clinical trials on HER2-positive breast tumors [6, 35], pCR after NAC with HER2-targeted agents may be a surrogate marker of prognosis; however, our results indicated that RFS was significantly better in patients with pCR after NAC with trastuzumab than in those with non-pCR.